YOLFTbeta
AptaBio Therapeutics Inc

AptaBio Therapeutics Inc

293780 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

4,495.00KRW-175.00 (-3.75%)

Price History

Full chart

Market Stats

Previous Close4,670.00
Open4,670.00
Day Range4,410.00 – 4,670.00
52-Week Range3,870.00 – 10,890.00
Volume65.06K
Market Cap219.13B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.98
50-Day Avg6,039.50
200-Day Avg6,784.13

About

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical needs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX reagents for transfecting DNA or RNA into eukaryotic cells. The company was founded in 2009 and is based in Yongin-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEODr. Jin Lee Soo
  • Employees41
  • HeadquartersHeungdeok IT Valley, 13, Yongin-si, South Korea, 16954, Korea
  • Websitehttps://www.aptabio.com

Leadership

  • Dr. Jin Lee SooChief Executive Officer
  • Dr. Hwan Moon SungPresident & CSO

Financials

Income Statement

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue300.06M1.45B1.02B341.04M223.68M48.35M323.87M3.36B3.70B
Growth (%)-+384.60%-29.95%-66.52%-34.41%-78.38%+569.80%+937.76%+10.02%
Cost of Revenue------245.37M3.07B2.37B
Gross Profit---341.04M223.68M48.35M78.50M286.62M1.33B
Gross Margin---100.00%100.00%100.00%24.24%8.53%35.97%
Operating Expense---6.41B11.59B9.56B16.45B19.14B16.87B
Operating Income-2.14B-3.36B-7.15B-6.06B-11.37B-9.51B-16.37B-18.85B-15.54B
Operating Margin-712.17%-231.21%-702.06%-1778.30%-5081.88%-19661.23%-5055.61%-560.98%-420.14%
EBITDA------10.08B-12.97B-23.87B-12.73B
EBITDA Margin------20837.70%-4004.64%-710.22%-344.34%
Net Income-31.12B-4.06B-6.30B-3.92B-10.69B-10.56B-12.06B-29.38B-16.35B
Net Income Margin-10372.02%-279.42%-618.31%-1149.08%-4778.80%-21849.25%-3724.24%-874.09%-442.04%
R&D---3.83B9.08B6.20B12.38B14.59B10.50B
R&D as % of Total Revenue---1122.70%4058.61%12816.45%3822.68%434.12%283.96%
Interest Expense00018.53M24.23M24.23M39.01M55.81M2.12B
Interest Expense % of Total Revenue0.00%0.00%0.00%5.43%10.83%50.11%12.04%1.66%57.27%

Balance Sheet

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.00B20.33B77.40B75.44B64.91B56.11B92.52B77.43B60.03B
Total Liabilities42.54B2.02B2.25B3.40B3.25B3.74B31.16B23.24B12.84B
Total Equity-31.54B18.31B75.16B72.04B61.67B52.37B61.36B54.20B47.18B
Cash55.00K137.00K16.60B14.69B6.57B1.99B25.02B25.54B16.08B
Total Debt4.82B-61.10M34.93M-----

Cash Flow

Currency: KRW2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.79B-1.75B-6.00B-3.79B-8.90B-6.83B-14.10B-12.16B-15.28B
Investing Cash Flow-172.04M-7.68B-44.53B371.48M1.13B1.74B-12.74B12.85B-
Financing Cash Flow010.92B62.81B1.51B-375.68M496.01M49.85B-167.31M-
Capital Expenditure8.86M27.68M2.78B1.69B161.67M1.04B167.39M240.16M58.67M
Free Cash Flow----5.86B-9.07B-8.02B-14.26B-12.40B-15.33B
FCF to OCF---154.85%101.90%117.36%101.19%101.98%100.38%

Earnings

Report DateJun 30, 2019Nov 14, 2019Jan 28, 2020May 14, 2020Aug 14, 2020Nov 12, 2020Jan 28, 2021May 14, 2021Aug 12, 2021Nov 15, 2021Mar 22, 2022Mar 31, 2022Jun 30, 2022Sep 30, 2022Jan 31, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Mar 29, 2024Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------------------
EPS Actual-32.77-84.39-89.59-43.00-16.00-28.00-91.96-142.30-93.70-199.96-105.00-116.80-151.77-206.90-115.11-200.39-96.51-183.55-372.57-169.98-301.35-347.99-404.30-95.96-157.24-114.13-240.15-229.4139.71
Surprise-----------------------------
Timing-After-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hours-Pre-market---Pre-market---Pre-market----------

Key Statistics & Ratios

Market Cap219.13B
Enterprise Value170.67B
Trailing P/E0.00
Forward P/E0.00
Price / Sales46.10
Price / Book4.30
Revenue (TTM)4.75B
Gross Profit (TTM)2.24B
EBITDA-18.32B
Profit Margin0.00%
Operating Margin-223.03%
Return on Equity-33.15%
Return on Assets-18.89%
Shares Outstanding28.09M
Shares Float19.50M
Beta0.98
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 24, 20212:1